Melo Media, Monday, 13th November, 2023
According to Bradley Chingobe, Senior Manager of Public Relations at the Zambia Medicines and Medical Supplies Agency (ZAMMSA), there are no defective Erythromycin drugs currently on the market. Chingobe assures that the medication is safe for use.
In the ZAMMSA case, the drug supplier, Missionpharma, has raised a defense claiming that the Erythromicin in question is not defective. To support their claim, they have requested that the drug be tested by an independent laboratory. They believe that the test results will prove that there is nothing wrong with the drug.
In the recent ZAMMSA case, Health Minister Sylva Masebo informed Parliament that the Erythromycin drugs procured by ZAMMSA were found to be defective. These drugs were included in the last consignment that was delivered.
In a subsequent interview, Chingobe stated that the Erythromycin that was found to be defective was removed from the non-compliant health kits. However, the Erythromycin in the health kits that were the subject of the complaint was distributed because it was determined to be free of any issues.